NCT04895137View on ClinicalTrials.gov

mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Colorectal CancerImmunotherapy
Interventions
DRUG

mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations

mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colorectal cancer

Trial Locations (1)

Unknown

Sun Yatsen University, Guangzhou

All Listed Sponsors
lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER